DBVT

DBV Technologies S.A.

Recommendation Details

PortfolioSmallcap Short

DateNov 12, 2026

ForecastQ Daily Probabilities

100.0%

33.3%

26.5%

Company Description

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.

Recent News & Events

Near-term direction hinges on FDA BLA filing acceptance and Priority Review decision expected in Q4 2026, offset by going-concern overhang and dilution risk; binary catalyst skews risk/reward but with high volatility.

Regulatory Milestone (FDA Filing Acceptance / Priority Review Decision)

FDA BLA acceptance and Priority Review decision expected Q4 2026

DBV submitted the BLA for the VIASKIN Peanut Patch (ages 4-7) on Sept 29, 2026 and requested Priority Review. The FDA is expected to determine in Q4 2026 whether the filing is sufficiently complete to begin substantive review and whether Priority Review is granted. A positive acceptance/Priority Review decision would be a near-term binary catalyst likely to lift shares, while a refusal-to-file or standard-review designation would pressure the stock.

DBV Technologies Press Release

Going Concern Warning / Financing Risk

Substantial doubt going-concern disclosure and dilution risk

In Q3 2026 results, management concluded existing cash ($165.7M as of Sept 30) is insufficient to fund operations for at least twelve months, raising substantial doubt about going concern despite runway into Q3 2027. The company is evaluating ATM sales, equity transactions, and warrant exercises, creating near-term dilution overhang that weighed on shares (down ~8% post-report).

DBV Technologies Press Release

Analyst Rating Action

Citizens cuts price target to $47 on BLA delay, keeps Outperform

Citizens lowered its DBVT price target to $47 from $55 while maintaining a Market Outperform rating, citing BLA timing/delay concerns. The reduced target still implies substantial upside from ~$10.65, but the cut signals tempered near-term expectations around the regulatory timeline.

Investing.com

Manufacturing / Regulatory Risk (Contract Manufacturer Remediation)

Fareva remediation and FDA pre-approval inspection timing

DBV continues remediation work with contract manufacturer Fareva following the April 2026 FDA Warning Letter; the target PAI date in the BLA falls after Fareva expects to complete remediation. Any negative FDA feedback on manufacturing readiness or PAI scheduling could threaten approval timing and pressure shares.

DBV Technologies Press Release

Corporate Update (Toddler Program / Rolling Submission)

FDA dialogue on potential rolling submission for toddler BLA

DBV is discussing a potential rolling submission for the 1-through-3 year toddler BLA, with submission expected in 2027 and an update pending finalization of FDA discussions. Progress here supports the broader franchise narrative but is unlikely to be an immediate price mover within two weeks.

DBV Technologies Press Release

DBVT

DBVT

Company Information

Recommendation Details

Company Description

Recent News & Events

FDA BLA acceptance and Priority Review decision expected Q4 2026

Substantial doubt going-concern disclosure and dilution risk

Citizens cuts price target to $47 on BLA delay, keeps Outperform

Fareva remediation and FDA pre-approval inspection timing

FDA dialogue on potential rolling submission for toddler BLA